Patients struggle with lack of consistent coverage for popular weight-loss drugsAccess to obesity treatments is hindered by inconsistent insurance coverage and high costs, making it difficult for many to maintain weight loss.
Medicare Will Not Cover GLP-1 Drugs for Weight LossMedicare and Medicaid will not cover weight-loss drugs for obesity treatment, affecting millions.
High demand for weight loss drugs like Ozempic and Wegovy is impacting employer health care costs-but it can be critical for retaining talentEmployers are increasingly offering health benefits for weight loss drugs, impacting healthcare costs amidst high demand and rising obesity rates.
Decades-old law limits access to Wegovy for Medicaid beneficiariesMedicaid plans not required to cover Wegovy for weight loss/obesity, despite effectiveness, due to old law.
Which Weight-Loss Drug Is Better: Wegovy or Zepbound?Zepbound leads to more weight loss than Wegovy in clinical trials.
A New Test Predicts Who Will Benefit Most from Weight-Loss DrugsGenetic test MyPhenome can predict response to weight-loss drug semaglutide with 75% accuracy, categorizing people into four types of weight gain.
Patients struggle with lack of consistent coverage for popular weight-loss drugsAccess to obesity treatments is hindered by inconsistent insurance coverage and high costs, making it difficult for many to maintain weight loss.
Medicare Will Not Cover GLP-1 Drugs for Weight LossMedicare and Medicaid will not cover weight-loss drugs for obesity treatment, affecting millions.
High demand for weight loss drugs like Ozempic and Wegovy is impacting employer health care costs-but it can be critical for retaining talentEmployers are increasingly offering health benefits for weight loss drugs, impacting healthcare costs amidst high demand and rising obesity rates.
Decades-old law limits access to Wegovy for Medicaid beneficiariesMedicaid plans not required to cover Wegovy for weight loss/obesity, despite effectiveness, due to old law.
Which Weight-Loss Drug Is Better: Wegovy or Zepbound?Zepbound leads to more weight loss than Wegovy in clinical trials.
A New Test Predicts Who Will Benefit Most from Weight-Loss DrugsGenetic test MyPhenome can predict response to weight-loss drug semaglutide with 75% accuracy, categorizing people into four types of weight gain.
Obesity-drug pioneers and 13,508 physicists win US$3-million Breakthrough PrizesThe scientists behind GLP-1 based weight-loss drugs Ozempic and Wegovy received a $3 million Breakthrough Prize for their life-saving contributions.
Drugmakers and pharmacists battle over who gets to make obesity drugsDemand for Ozempic and its alternatives has led to compounded versions, but brand manufacturers are actively trying to eliminate this competition.
Elon Musk dubs himself "Ozempic Santa" as weight loss drugs go mainstreamElon Musk's use of an anti-obesity drug signals a shift towards mainstream acceptance and discussion of weight-loss medications.
The Future of Ozempic Is Coming Into FocusThe rising popularity of Ozempic alternatives continues despite expected supply increases due to significant pricing differences.
How little Denmark got homegrown giant Novo Nordisk to lower Ozempic pricesPharmaceutical pricing conflicts raise challenges globally, as Denmark struggles to afford Novo Nordisk's drugs despite their local production.
Insider Today: Austin's genius housing fixThe soaring prices of weight-loss drugs in the US lead to significant consumer challenges compared to prices in other countries.
Obesity-drug pioneers and 13,508 physicists win US$3-million Breakthrough PrizesThe scientists behind GLP-1 based weight-loss drugs Ozempic and Wegovy received a $3 million Breakthrough Prize for their life-saving contributions.
Drugmakers and pharmacists battle over who gets to make obesity drugsDemand for Ozempic and its alternatives has led to compounded versions, but brand manufacturers are actively trying to eliminate this competition.
Elon Musk dubs himself "Ozempic Santa" as weight loss drugs go mainstreamElon Musk's use of an anti-obesity drug signals a shift towards mainstream acceptance and discussion of weight-loss medications.
The Future of Ozempic Is Coming Into FocusThe rising popularity of Ozempic alternatives continues despite expected supply increases due to significant pricing differences.
How little Denmark got homegrown giant Novo Nordisk to lower Ozempic pricesPharmaceutical pricing conflicts raise challenges globally, as Denmark struggles to afford Novo Nordisk's drugs despite their local production.
Insider Today: Austin's genius housing fixThe soaring prices of weight-loss drugs in the US lead to significant consumer challenges compared to prices in other countries.
How Much Should Weight Loss Drugs Like Wegovy and Zepbound Cost?The cost of weight loss drugs Wegovy and Zepbound outweighs their health benefits, as per a study from the University of Chicago.
FDA approves weight loss drug Zepbound to treat obstructive sleep apneaZepbound is the first FDA-approved drug for treating sleep apnea linked to obesity.The drug aids in weight loss, which alleviates sleep apnea symptoms effectively.
Lilly sells Zepbound vials at 50% discount to meet weight loss drug demandEli Lilly launches Zepbound vials at lower prices to address supply shortages and boost access for patients.
Eli Lilly just halved the price of its weight-loss drug - declaring war on the booming market of knock-offsEli Lilly is significantly reducing the price of Zepbound to $399-$549 to combat counterfeits and enhance patient access.
Eli Lilly just made its weight-loss drug cheaper with a simple design tweakEli Lilly's new Zepbound vials improve drug access and affordability despite increased user difficulty compared to autoinjector pens.
Eli Lilly Has a Major Problem With Its Weight Loss Drugs Zepbound and MounjaroEli Lilly's Zepbound missed sales estimates, raising concerns over the demand for popular weight loss drugs.
How Much Should Weight Loss Drugs Like Wegovy and Zepbound Cost?The cost of weight loss drugs Wegovy and Zepbound outweighs their health benefits, as per a study from the University of Chicago.
FDA approves weight loss drug Zepbound to treat obstructive sleep apneaZepbound is the first FDA-approved drug for treating sleep apnea linked to obesity.The drug aids in weight loss, which alleviates sleep apnea symptoms effectively.
Lilly sells Zepbound vials at 50% discount to meet weight loss drug demandEli Lilly launches Zepbound vials at lower prices to address supply shortages and boost access for patients.
Eli Lilly just halved the price of its weight-loss drug - declaring war on the booming market of knock-offsEli Lilly is significantly reducing the price of Zepbound to $399-$549 to combat counterfeits and enhance patient access.
Eli Lilly just made its weight-loss drug cheaper with a simple design tweakEli Lilly's new Zepbound vials improve drug access and affordability despite increased user difficulty compared to autoinjector pens.
Eli Lilly Has a Major Problem With Its Weight Loss Drugs Zepbound and MounjaroEli Lilly's Zepbound missed sales estimates, raising concerns over the demand for popular weight loss drugs.
Compounded Wegovy and Zepbound may disappear under new FDA rulesThe FDA is restricting compound versions of popular weight-loss drugs due to increased supply from original manufacturers.
Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-OldsNovo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.
Weight-loss drug firm accused of prioritising profits after halting insulin pen productionNovo Nordisk's decision to halt production of insulin pens raises ethical concerns over prioritizing profits from weight-loss drugs over patients' health.
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelmsCagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.
Compounded Wegovy and Zepbound may disappear under new FDA rulesThe FDA is restricting compound versions of popular weight-loss drugs due to increased supply from original manufacturers.
Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-OldsNovo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.
Weight-loss drug firm accused of prioritising profits after halting insulin pen productionNovo Nordisk's decision to halt production of insulin pens raises ethical concerns over prioritizing profits from weight-loss drugs over patients' health.
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelmsCagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.
Eilis O'Hanlon on The Skinny Jab Revolution: Is replacing the pleasure that food can bring with the joyless asceticism of drugs really the only solution?'Kathryn Thomas's documentary critically examines the implications of weight-loss drugs, emphasizing the balance of convenience against long-term health effects.
'In the States, they're injecting 12-year-olds. That isn't here yet, but it's on the way' - Kathryn Thomas on her weight-loss drugs documentaryWeight-loss drugs are easily obtainable, but caution is advised due to personal and ethical concerns.
'Fake weight loss drug nearly killed me'Be cautious about purchasing weight loss drugs online; they may not be safe or legitimate.
Eilis O'Hanlon on The Skinny Jab Revolution: Is replacing the pleasure that food can bring with the joyless asceticism of drugs really the only solution?'Kathryn Thomas's documentary critically examines the implications of weight-loss drugs, emphasizing the balance of convenience against long-term health effects.
'In the States, they're injecting 12-year-olds. That isn't here yet, but it's on the way' - Kathryn Thomas on her weight-loss drugs documentaryWeight-loss drugs are easily obtainable, but caution is advised due to personal and ethical concerns.
'Fake weight loss drug nearly killed me'Be cautious about purchasing weight loss drugs online; they may not be safe or legitimate.
The FDA says patients may be overdosing on imitation semaglutide weight-loss drugs because the directions are unclearConsumers overdosing on knock-off semaglutide weight-loss drugs.
HIMS Stock Craters - Is It a Buying Opportunity?Hims & Hers Health faces challenges after the FDA resolved the semaglutide shortage, impacting their growth from compounding drug sales.
Drugmaker shut down after black schmutz found in injectable weight-loss drugFDA warns about safety issues with compounded weight-loss drugs as pharmaceutical companies fight against them amid legal battles and differing interests.
The FDA says patients may be overdosing on imitation semaglutide weight-loss drugs because the directions are unclearConsumers overdosing on knock-off semaglutide weight-loss drugs.
HIMS Stock Craters - Is It a Buying Opportunity?Hims & Hers Health faces challenges after the FDA resolved the semaglutide shortage, impacting their growth from compounding drug sales.
Drugmaker shut down after black schmutz found in injectable weight-loss drugFDA warns about safety issues with compounded weight-loss drugs as pharmaceutical companies fight against them amid legal battles and differing interests.
Weight-loss drugs aren't just slimming waists. They're shifting the economy.Weight-loss drugs are reshaping consumer habits and spending patterns, leading to a potential economic impact of billions.Healthier weight-loss with GLP-1 drugs could boost GDP significantly.
Scientists Are Studying Weight-Loss Drugs for Way More Than Weight LossWeight-loss drugs like Wegovy and Zepbound, based on GLP-1, have broader applications beyond weight loss and diabetes.
A scientist tested knock-off Ozempic sold online. He found dangerous ingredients and doses - and got scammed out of money.The rise in demand for weight-loss drugs has led consumers to purchase potentially dangerous gray market alternatives online.
Weight-loss drugs aren't just slimming waists. They're shifting the economy.Weight-loss drugs are reshaping consumer habits and spending patterns, leading to a potential economic impact of billions.Healthier weight-loss with GLP-1 drugs could boost GDP significantly.
Scientists Are Studying Weight-Loss Drugs for Way More Than Weight LossWeight-loss drugs like Wegovy and Zepbound, based on GLP-1, have broader applications beyond weight loss and diabetes.
A scientist tested knock-off Ozempic sold online. He found dangerous ingredients and doses - and got scammed out of money.The rise in demand for weight-loss drugs has led consumers to purchase potentially dangerous gray market alternatives online.
New weight-loss drugs like Mounjaro are hot right now. Eli Lilly's CEO explains why they're so expensive.Weight-loss drugs are expensive due to the high development costs and the limited time to recoup investment before patents expire.
Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese AmericansMillions of Americans with obesity may gain Medicare/Medicaid coverage for weight-loss drugs, marking a significant policy shift and potential cost-saving.
Biden proposes Medicare and Medicaid cover weight-loss drugs like Wegovy and Ozempic for millions of obese AmericansMillions of Americans with obesity may soon have weight-loss drugs like Wegovy or Ozempic covered by Medicare or Medicaid under a new Biden administration rule.
Armed Bandits in Brazil Pursue New Loot: OzempicPharmacists in Sao Paulo are facing armed robberies for sought-after weight-loss drugs amid rising obesity rates and economic struggles.
This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street InsiderEli Lilly's stock has declined sharply but remains a focus for bullish analysts.The company faces challenges with weight loss drugs affecting revenue projections.
Unemployed Brits will receive free Ozempic-style weight-loss shots to help them get jobsThe British government views weight loss drugs as a potential solution to chronic unemployment linked to obesity-related health issues.
New weight-loss drugs like Mounjaro are hot right now. Eli Lilly's CEO explains why they're so expensive.Weight-loss drugs are expensive due to the high development costs and the limited time to recoup investment before patents expire.
Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese AmericansMillions of Americans with obesity may gain Medicare/Medicaid coverage for weight-loss drugs, marking a significant policy shift and potential cost-saving.
Biden proposes Medicare and Medicaid cover weight-loss drugs like Wegovy and Ozempic for millions of obese AmericansMillions of Americans with obesity may soon have weight-loss drugs like Wegovy or Ozempic covered by Medicare or Medicaid under a new Biden administration rule.
Armed Bandits in Brazil Pursue New Loot: OzempicPharmacists in Sao Paulo are facing armed robberies for sought-after weight-loss drugs amid rising obesity rates and economic struggles.
This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street InsiderEli Lilly's stock has declined sharply but remains a focus for bullish analysts.The company faces challenges with weight loss drugs affecting revenue projections.
Unemployed Brits will receive free Ozempic-style weight-loss shots to help them get jobsThe British government views weight loss drugs as a potential solution to chronic unemployment linked to obesity-related health issues.
US obesity rates drop for 1st time in a decade, with possible help from weight loss medicationsObesity rates in the U.S. showed a slight decline from 46% to 45.6%, marking the first decrease in over a decade.
Science in 2025: the events to watch for next yearEmerging obesity treatments like orforglipron and retatrutide show significant potential, possibly transforming the landscape of weight loss drugs in 2025.
Teenagers Are Taking New Weight-Loss Drugs, but the Science Is Far from SettledTeenagers are increasingly being prescribed semaglutide drugs, raising concerns about long-term health impacts.
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, WegovyVerdiva has raised $410 million to develop oral drugs for obesity, challenging established players by addressing unmet medical needs in weight loss.
How will weight-loss drugs change our relationship with food?Weight-loss drugs are reshaping the conversation around obesity, challenging moral stigmas and impacting societal attitudes toward health and personal responsibility.
Ozempic is about to get a lot cheaper. If Trump can agree to a Biden-era idea:The Biden administration proposes covering weight-loss injectables under Medicare and Medicaid, potentially aiding millions of obese Americans.
US obesity rates drop for 1st time in a decade, with possible help from weight loss medicationsObesity rates in the U.S. showed a slight decline from 46% to 45.6%, marking the first decrease in over a decade.
Science in 2025: the events to watch for next yearEmerging obesity treatments like orforglipron and retatrutide show significant potential, possibly transforming the landscape of weight loss drugs in 2025.
Teenagers Are Taking New Weight-Loss Drugs, but the Science Is Far from SettledTeenagers are increasingly being prescribed semaglutide drugs, raising concerns about long-term health impacts.
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, WegovyVerdiva has raised $410 million to develop oral drugs for obesity, challenging established players by addressing unmet medical needs in weight loss.
How will weight-loss drugs change our relationship with food?Weight-loss drugs are reshaping the conversation around obesity, challenging moral stigmas and impacting societal attitudes toward health and personal responsibility.
Ozempic is about to get a lot cheaper. If Trump can agree to a Biden-era idea:The Biden administration proposes covering weight-loss injectables under Medicare and Medicaid, potentially aiding millions of obese Americans.
Weight-loss drugs may boost health in many waysWeight-loss drugs can improve heart health and reduce the risk of mental illness, but they also have risks, including increased joint pain and pancreatitis.
Could Ozempic treat addiction?GLP-1 receptor agonists may reduce cravings not just for food but also for drugs and alcohol, aiding recovery from addiction.
Weight-loss drugs may boost health in many waysWeight-loss drugs can improve heart health and reduce the risk of mental illness, but they also have risks, including increased joint pain and pancreatitis.
Could Ozempic treat addiction?GLP-1 receptor agonists may reduce cravings not just for food but also for drugs and alcohol, aiding recovery from addiction.
Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.Blue Cross Blue Shield of Michigan has limited coverage for weight-loss drugs, impacting thousands who rely on them for health and well-being.
Maker of weight-loss drugs to ask Trump to pause price negotiations: ReportBiden administration proposed allowing Medicare to cover anti-obesity medications to improve long-term health and reduce future costs.CBO predicts Medicare's anti-obesity drug coverage would lead to significant net costs for taxpayers.
Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.Blue Cross Blue Shield of Michigan has limited coverage for weight-loss drugs, impacting thousands who rely on them for health and well-being.
Maker of weight-loss drugs to ask Trump to pause price negotiations: ReportBiden administration proposed allowing Medicare to cover anti-obesity medications to improve long-term health and reduce future costs.CBO predicts Medicare's anti-obesity drug coverage would lead to significant net costs for taxpayers.
Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More - MedCity NewsMetabolic medicine dominated life sciences in 2024, driven by weight loss drugs and new market entrants.
Weight-loss drugs can improve kidney health, study findsGLP-1 receptor agonists significantly lower the risk of kidney failure, worsening kidney function, and death due to kidney disease by approximately 19%.
Medicaid dominates coverage of Novo, Lilly weight-loss drugsGovernment health plans overwhelmingly dominate coverage for weight-loss drugs, covering over 52 million Americans compared to about 24 million in private plans.
Vogue boss 'concerned' by return to skinny modelsThe fashion industry is shifting back to favoring skinny models, raising concerns about body diversity and the influence of weight-loss drugs like Ozempic.
Americans seeking Eli Lilly and Novo Nordisk's weight-loss drugs turn to compounded marketPatients are struggling to obtain weight-loss and diabetes medications due to supply issues and insurance problems, turning instead to cheaper online alternatives.
Weight loss market: Eli Lilly and Novo Nordisk's rivals muscle inSmaller competitors are preparing to enter the weight-loss drug market dominated by Eli Lilly and Novo Nordisk.
Americans seeking Eli Lilly and Novo Nordisk's weight-loss drugs turn to compounded marketPatients are struggling to obtain weight-loss and diabetes medications due to supply issues and insurance problems, turning instead to cheaper online alternatives.
Weight loss market: Eli Lilly and Novo Nordisk's rivals muscle inSmaller competitors are preparing to enter the weight-loss drug market dominated by Eli Lilly and Novo Nordisk.
Ozempic may help battle drug and alcohol addictionWeight-loss drugs Ozempic and Mounjaro may help reduce substance abuse cravings and binging, showing protective effects on overdose and binge drinking rates.
Unemployed to be given weight-loss jab to help them back into work, government saysEli Lilly invests £279 million in UK's life sciences for weight-loss jab trials aimed at reducing unemployment and health burdens.
Has Eli Lilly Destroyed Hims & Hers Upside?Hims & Hers Health capitalized on weight-loss drug market trends while facing new competition from Eli Lilly's FDA-approved product offerings.
Unemployed to be given weight-loss jab to help them back into work, government saysEli Lilly invests £279 million in UK's life sciences for weight-loss jab trials aimed at reducing unemployment and health burdens.
Has Eli Lilly Destroyed Hims & Hers Upside?Hims & Hers Health capitalized on weight-loss drug market trends while facing new competition from Eli Lilly's FDA-approved product offerings.
Ozempic may help manage opioid addiction: studySemaglutide (Ozempic) significantly reduces the likelihood of opioid overdoses in patients with a history of opioid abuse, offering potential in addiction management.
Weight-loss drugs slow down the ageing process', scientists suggestWeight-loss drugs like semaglutide may significantly enhance longevity and health by reducing overall mortality rates.
Ozempic may help manage opioid addiction: studySemaglutide (Ozempic) significantly reduces the likelihood of opioid overdoses in patients with a history of opioid abuse, offering potential in addiction management.
Weight-loss drugs slow down the ageing process', scientists suggestWeight-loss drugs like semaglutide may significantly enhance longevity and health by reducing overall mortality rates.
New Weight Loss Drug Has Small Problem: Uncontrollable VomitingRoche's weight loss drug CT-388 shows high vomiting rates in trials, raising concerns for investors.
3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024Nvidia is the leading AI stock, but other companies are outperforming it in 2024.
3 GLP-1 Stocks to Buy Now For Big Long-Term GainsWeight loss drug market shows impressive growth, driven by GLP-1 agonists.New potential applications for these drugs could significantly expand the market.Positive investor sentiment around biotech companies focused on weight loss drugs.
Obesity drugs aren't always forever. What happens when you quit?GLP-1 agonists are popular weight-loss drugs, but many people discontinue due to cost, side effects, and other factors. Stopping these medications can lead to weight regain.
3 GLP-1 Stocks to Buy Now For Big Long-Term GainsWeight loss drug market shows impressive growth, driven by GLP-1 agonists.New potential applications for these drugs could significantly expand the market.Positive investor sentiment around biotech companies focused on weight loss drugs.
Obesity drugs aren't always forever. What happens when you quit?GLP-1 agonists are popular weight-loss drugs, but many people discontinue due to cost, side effects, and other factors. Stopping these medications can lead to weight regain.
America's doctors need more obesity medicine trainingThere is a shortage of healthcare providers trained in obesity care to meet the growing demand for weight-loss drugs.
The next food marketing blitz is aimed at people on new weight-loss drugsAs new weight-loss drugs become popular, food manufacturers are adapting to cater to consumers on these medications.
Hims & Hers to sell inexpensive Ozempic alternativeOnline pharmaceutical brands Hims & Hers are introducing a cost-effective weight-loss drug with semaglutide.
"Outrageously" priced weight-loss drugs could bankrupt US health careThe rise of effective weight-loss drugs could significantly impact America's high obesity rate and prescription drug pricing, potentially exerting a massive financial strain on the healthcare system.